- SynonymVEGFC,Flt4-L,VRP
- SourceHuman VEGF-C, His Tag (VEC-H4225) is expressed from human 293 cells (HEK293). It contains AA Thr 103 - Arg 227(Accession # AAH35212.1).Predicted N-terminus: Thr 103Request for sequence
- Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 14.9 kDa. The protein migrates as 19-25 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehaloseis added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human VEGF-C, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) at 5 μg/mL (100 μL/well) can bind Human VEGF-C, His Tag (Cat. No. VEC-H4225) with a linear range of 2-20 ng/mL (QC tested).
Immobilized Human VEGF-C, His Tag (Cat. No. VEC-H4225) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R1, His,Avitag (Cat. No. VE1-H82E3) with a linear range of 0.02-0.625 μg/mL (Routinely tested).
- Citations
PEG-immobilized keratin for protein drug sequestration and pH-mediated delivery
Authors: de Guzman RC, et al.
Journal: J Drug Deliv 2016
Application: Cell Culture
Request for Full-text
- BackgroundVascular endothelial growth factor C is also known as VEGFC, Flt4-L and VRP, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis, lymphangiogenesis and endothelial cell growth and survival, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor D (VEGF-D). VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Overexpression of VEGF-C causes lymphatics to enlarge possibly facilitates metastasis.
- References
- (1)Orpana A, Salven P , 2003, Leuk. Lymphoma 43 (2): 219–24.
- (2)Joukov V, et al., 1996, EMBO J., 15(2): 290-98.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
